Skip to main content

Table 4 Variables associated with overall survival among 284 patients

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Co-variable No. Univariate analysis Multivariate analysis
   MST (months)  P  Variate OR 95% CI  P
Age        
 < 70 231 22.8      
 > 70 53 24.3 0.625     
Gender        
 Male 168 20.1      
 Female 116 32.4 0.0086 Female 1.06 0.75-1.58 0.75
Smoking status        
 Yes 174 20.1      
 No 110 33.4 0.0012 No smoking status 0.84 0.52-1.24 0.39
ECOG PS        
 0-1 238 29.5      
 >2 46 7.9 <.0001 PS 0-1 0.34 0.24-0.50 <.0001
Stage        
 IIIB 25 30.2      
 IV 259 22.5 0.269     
EGFR mutation        
 Mt (+) 121 39.2      
 Mt (−) 163 17.8 <.0001 Mutant EGFR 0.53 0.34-0.84 0.0069
PCV        
 < 2.2 ng/ml 150 38.6      
 ≥ 2.2 ng/ml 134 15.0 <.0001 < 2.2 ng/ml 0.43 0.31-0.59 <.0001
CEA        
 < 5.0 ng/ml 108 32.6      
 ≥ 5.0 ng/ml 176 21.0 0.036 < 5.0 ng/ml 0.93 0.67-1.26 0.63
Start dates of IT        
 Before 1/ 4/ 2008 79 34.1   After 1/ 4/ 2008    
 After 1/ 4/ 2008 205 19.3 0.0030   0.73 0.50-1.15 0.07
EGFR-TKI treatment        
 Yes 143 33.7      
 No 141 15.3 <.0001 Yes 0.76 0.50-1.15 0.20
  1. IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, M(−): wild-type EGFR.